This unique combination features Orforglipron, a non-peptide GLP-1 receptor agonist studied for its potential role in supporting metabolic function, paired with SLU-PP-332, a compound explored for its influence on energy metabolism and cellular performance. Together, they are being researched for their complementary effects on metabolic efficiency and energy regulation.